Probing the endogenous peptidomes of cancer for biomarkers

A new endeavor

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The life span of cancer patients can be prolonged with appropriate therapies if detected early. Mass screening for early detection of cancer, however, requires sensitive and specific biomarkers obtainable from body fluids such as blood or urine. To date, most biomarker discovery programs focus on the proteome rather than the endogenous peptidome. It has been long-established that tumor cells and stromal cells produce tumor resident proteases (TRPs) to remodel the surrounding tumor microenvironment in support of tumor progression. In fact, proteolytic products of TRPs have been shown to correlate with malignant behavior. Being of low molecular weight, these unique peptides can pass through the endothelial barrier of the vasculature into the bloodstream. As such, the cancer peptidome has increasingly become a focus for biomarker discovery. In this review, we discuss on the various aspects of the peptidome in cancer biomarker research.

Original languageEnglish
Title of host publicationAdvances in Clinical Chemistry
EditorsGregory S. Makowski
PublisherAcademic Press Inc.
Pages67-89
Number of pages23
ISBN (Print)9780128171431
DOIs
Publication statusPublished - 1 Jan 2019

Publication series

NameAdvances in Clinical Chemistry
Volume88
ISSN (Print)0065-2423
ISSN (Electronic)2162-9471

Fingerprint

Tumor Biomarkers
Tumors
Biomarkers
Neoplasms
Peptide Hydrolases
Body fluids
Proteome
Mass Screening
Tumor Microenvironment
Body Fluids
Stromal Cells
Screening
Early Detection of Cancer
Blood
Molecular weight
Cells
Molecular Weight
Peptides
Urine
Research

Keywords

  • Biomarker
  • Cancer
  • Peptidomics
  • Proteolysis

ASJC Scopus subject areas

  • Chemistry(all)
  • Clinical Biochemistry

Cite this

Lee, P. Y., Teck Yew, L., & A. Jamal, A. R. (2019). Probing the endogenous peptidomes of cancer for biomarkers: A new endeavor. In G. S. Makowski (Ed.), Advances in Clinical Chemistry (pp. 67-89). (Advances in Clinical Chemistry; Vol. 88). Academic Press Inc.. https://doi.org/10.1016/bs.acc.2018.10.004

Probing the endogenous peptidomes of cancer for biomarkers : A new endeavor. / Lee, Pey Yee; Teck Yew, Low; A. Jamal, A. Rahman.

Advances in Clinical Chemistry. ed. / Gregory S. Makowski. Academic Press Inc., 2019. p. 67-89 (Advances in Clinical Chemistry; Vol. 88).

Research output: Chapter in Book/Report/Conference proceedingChapter

Lee, PY, Teck Yew, L & A. Jamal, AR 2019, Probing the endogenous peptidomes of cancer for biomarkers: A new endeavor. in GS Makowski (ed.), Advances in Clinical Chemistry. Advances in Clinical Chemistry, vol. 88, Academic Press Inc., pp. 67-89. https://doi.org/10.1016/bs.acc.2018.10.004
Lee PY, Teck Yew L, A. Jamal AR. Probing the endogenous peptidomes of cancer for biomarkers: A new endeavor. In Makowski GS, editor, Advances in Clinical Chemistry. Academic Press Inc. 2019. p. 67-89. (Advances in Clinical Chemistry). https://doi.org/10.1016/bs.acc.2018.10.004
Lee, Pey Yee ; Teck Yew, Low ; A. Jamal, A. Rahman. / Probing the endogenous peptidomes of cancer for biomarkers : A new endeavor. Advances in Clinical Chemistry. editor / Gregory S. Makowski. Academic Press Inc., 2019. pp. 67-89 (Advances in Clinical Chemistry).
@inbook{9d01020729fa4f8d9bfd8c23a7da23a3,
title = "Probing the endogenous peptidomes of cancer for biomarkers: A new endeavor",
abstract = "The life span of cancer patients can be prolonged with appropriate therapies if detected early. Mass screening for early detection of cancer, however, requires sensitive and specific biomarkers obtainable from body fluids such as blood or urine. To date, most biomarker discovery programs focus on the proteome rather than the endogenous peptidome. It has been long-established that tumor cells and stromal cells produce tumor resident proteases (TRPs) to remodel the surrounding tumor microenvironment in support of tumor progression. In fact, proteolytic products of TRPs have been shown to correlate with malignant behavior. Being of low molecular weight, these unique peptides can pass through the endothelial barrier of the vasculature into the bloodstream. As such, the cancer peptidome has increasingly become a focus for biomarker discovery. In this review, we discuss on the various aspects of the peptidome in cancer biomarker research.",
keywords = "Biomarker, Cancer, Peptidomics, Proteolysis",
author = "Lee, {Pey Yee} and {Teck Yew}, Low and {A. Jamal}, {A. Rahman}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/bs.acc.2018.10.004",
language = "English",
isbn = "9780128171431",
series = "Advances in Clinical Chemistry",
publisher = "Academic Press Inc.",
pages = "67--89",
editor = "Makowski, {Gregory S.}",
booktitle = "Advances in Clinical Chemistry",
address = "United States",

}

TY - CHAP

T1 - Probing the endogenous peptidomes of cancer for biomarkers

T2 - A new endeavor

AU - Lee, Pey Yee

AU - Teck Yew, Low

AU - A. Jamal, A. Rahman

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The life span of cancer patients can be prolonged with appropriate therapies if detected early. Mass screening for early detection of cancer, however, requires sensitive and specific biomarkers obtainable from body fluids such as blood or urine. To date, most biomarker discovery programs focus on the proteome rather than the endogenous peptidome. It has been long-established that tumor cells and stromal cells produce tumor resident proteases (TRPs) to remodel the surrounding tumor microenvironment in support of tumor progression. In fact, proteolytic products of TRPs have been shown to correlate with malignant behavior. Being of low molecular weight, these unique peptides can pass through the endothelial barrier of the vasculature into the bloodstream. As such, the cancer peptidome has increasingly become a focus for biomarker discovery. In this review, we discuss on the various aspects of the peptidome in cancer biomarker research.

AB - The life span of cancer patients can be prolonged with appropriate therapies if detected early. Mass screening for early detection of cancer, however, requires sensitive and specific biomarkers obtainable from body fluids such as blood or urine. To date, most biomarker discovery programs focus on the proteome rather than the endogenous peptidome. It has been long-established that tumor cells and stromal cells produce tumor resident proteases (TRPs) to remodel the surrounding tumor microenvironment in support of tumor progression. In fact, proteolytic products of TRPs have been shown to correlate with malignant behavior. Being of low molecular weight, these unique peptides can pass through the endothelial barrier of the vasculature into the bloodstream. As such, the cancer peptidome has increasingly become a focus for biomarker discovery. In this review, we discuss on the various aspects of the peptidome in cancer biomarker research.

KW - Biomarker

KW - Cancer

KW - Peptidomics

KW - Proteolysis

UR - http://www.scopus.com/inward/record.url?scp=85059190528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059190528&partnerID=8YFLogxK

U2 - 10.1016/bs.acc.2018.10.004

DO - 10.1016/bs.acc.2018.10.004

M3 - Chapter

SN - 9780128171431

T3 - Advances in Clinical Chemistry

SP - 67

EP - 89

BT - Advances in Clinical Chemistry

A2 - Makowski, Gregory S.

PB - Academic Press Inc.

ER -